ArticleClinical and experimental medicine2026
Early detection and risk stratification of insulin resistance in children and adolescents with excess weight: a sdLDL/oxLDL-Based model.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Childhood excess weight is a significant risk factor for insulin resistance (IR), a key precursor to metabolic syndrome and type 2 diabetes. In epidemiologic studies, IR is commonly assessed by the homeostatic model assessment for insulin resistance (HOMA-IR). This study aimed to develop a small dense low-density lipoprotein (sdLDL) and oxidized low-density lipoprotein (oxLDL)-based model for the early detection and risk stratification of HOMA-IR-defined IR in children and adolescents with excess weight. A total of 510 children and adolescents with excess weight (aged 7-17 years) were enrolled and stratified into IR (n = 173) and non-IR (n = 337) groups according to HOMA-IR. Comprehensive anthropometric and biochemical parameters were collected, including comparative analyses of sdLDL, oxLDL, and triglyceride to high-density lipoprotein cholesterol (TG/HDL) ratio. Independent risk factors were identified through univariate and multivariate logistic regression, followed by development of a nomogram prediction model incorporating three lipid parameters and adjusted for age and sex. Model performance was evaluated using receiver operating characteristic curves, calibration analysis with bootstrap internal validation and decision curve analysis (DCA). Univariate analysis identified significant associations between IR and mean arterial pressure, TG/HDL, total cholesterol to HDL (TC/HDL) ratio, LDL to HDL (LDL/HDL) ratio, oxLDL, and sdLDL (all P < 0.05). Multivariate analysis confirmed TG/HDL (adjusted odds ratio [aOR] = 5.61, 95% confidence interval [CI]: 3.060-10.639, P < 0.001), oxLDL (aOR = 1.092, 95% CI: 1.065-1.120, P < 0.001), and sdLDL (aOR = 1.109, 95% CI: 1.076-1.146, P < 0.001) as independent risk factors. The final age- and sex-adjusted nomogram demonstrated strong discrimination (AUC = 0.836), good calibration (bootstrap-corrected mean absolute error = 0.012), and clear net clinical benefit across a wide range of decision thresholds based on DCA. Probability-based stratification enabled both continuous scoring and visual classification of individual IR risk. The developed age- and sex-adjusted nomogram combining TG/HDL ratio, sdLDL, and oxLDL demonstrates superior performance for predicting IR in children and adolescents with excess weight. By integrating continuous risk scoring with clinically actionable risk stratification, this tool supports early identification and tiered management in both screening and clinical decision-making settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.